BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37558271)

  • 1. Is neglect of self-clearance biasing TB vaccine impact estimates?
    Scarponi D; Clark RA; Weerasuriya CK; Emery J; Houben RMGJ; White R; McCreesh N
    BMJ Glob Health; 2023 Aug; 8(8):. PubMed ID: 37558271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is neglect of self-clearance biassing TB vaccine impact estimates?
    Scarponi D; Clark RA; Weerasuriya C; Emery JC; Houben RM; White RG; McCreesh N
    medRxiv; 2023 May; ():. PubMed ID: 37090535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New tuberculosis vaccines in India: modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01
    Clark RA; Weerasuriya CK; Portnoy A; Mukandavire C; Quaife M; Bakker R; Scarponi D; Harris RC; Rade K; Mattoo SK; Tumu D; Menzies NA; White RG
    BMC Med; 2023 Aug; 21(1):288. PubMed ID: 37542319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential impact of tuberculosis vaccines in China, South Africa, and India.
    Harris RC; Sumner T; Knight GM; Zhang H; White RG
    Sci Transl Med; 2020 Oct; 12(564):. PubMed ID: 33028708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-clearance of
    Emery JC; Richards AS; Dale KD; McQuaid CF; White RG; Denholm JT; Houben RMGJ
    Proc Biol Sci; 2021 Jan; 288(1943):20201635. PubMed ID: 33467995
    [No Abstract]   [Full Text] [Related]  

  • 6. Age-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling study.
    Harris RC; Sumner T; Knight GM; Evans T; Cardenas V; Chen C; White RG
    Lancet Glob Health; 2019 Feb; 7(2):e209-e218. PubMed ID: 30630775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China.
    Weerasuriya CK; Harris RC; McQuaid CF; Bozzani F; Ruan Y; Li R; Li T; Rade K; Rao R; Ginsberg AM; Gomez GB; White RG
    BMC Med; 2021 Feb; 19(1):60. PubMed ID: 33632218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects for a vaccine to prevent HIV-related tuberculosis.
    Nemes E; Scriba TJ; Hatherill M
    Curr Opin HIV AIDS; 2018 Nov; 13(6):522-527. PubMed ID: 30080682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New tuberculosis vaccines in India: Modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01
    Clark RA; Weerasuriya CK; Portnoy A; Mukandavire C; Quaife M; Bakker R; Scarponi D; Harris RC; Rade K; Mattoo SK; Tumu D; Menzies NA; White RG
    medRxiv; 2023 Jul; ():. PubMed ID: 36865172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model-based impact evaluation of new tuberculosis vaccines in aging populations under different modeling scenarios: the case of China.
    Tovar M; Sanz J; Moreno Y
    Front Public Health; 2024; 12():1302688. PubMed ID: 38463158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential health and economic impacts of new tuberculosis vaccines under varying delivery strategies in Delhi and Gujarat, India: a modelling study.
    Clark RA; Portnoy A; Weerasuriya CK; Sumner T; Bakker R; Harris RC; Rade K; Mattoo SK; Tumu D; Menzies NA; White RG
    medRxiv; 2023 Sep; ():. PubMed ID: 37808744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential impact of spatially targeted adult tuberculosis vaccine in Gujarat, India.
    Shrestha S; Chatterjee S; Rao KD; Dowdy DW
    J R Soc Interface; 2016 Mar; 13(116):. PubMed ID: 27009179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study.
    Clark RA; Mukandavire C; Portnoy A; Weerasuriya CK; Deol A; Scarponi D; Iskauskas A; Bakker R; Quaife M; Malhotra S; Gebreselassie N; Zignol M; Hutubessy RCW; Giersing B; Jit M; Harris RC; Menzies NA; White RG
    Lancet Glob Health; 2023 Apr; 11(4):e546-e555. PubMed ID: 36925175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing whole mycobacteria cell vaccines for tuberculosis: Workshop proceedings, Max Planck Institute for Infection Biology, Berlin, Germany, July 9, 2014.
    Whole Mycobacteria Cell Vaccines for Tuberculosis Summary Group
    Vaccine; 2015 Jun; 33(26):3047-55. PubMed ID: 25882170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tuberculosis: Current Status, Diagnosis, Treatment and Development of Novel Vaccines.
    Yadav J; Verma S; Chaudhary D; Jaiwal PK; Jaiwal R
    Curr Pharm Biotechnol; 2019; 20(6):446-458. PubMed ID: 31208308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine.
    Gupta N; Garg S; Vedi S; Kunimoto DY; Kumar R; Agrawal B
    Front Immunol; 2018; 9():2371. PubMed ID: 30386336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG?
    Martín C
    Eur Respir J; 2005 Jul; 26(1):162-7. PubMed ID: 15994403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New tuberculosis vaccines: advances in clinical development and modelling.
    Weerasuriya CK; Clark RA; White RG; Harris RC
    J Intern Med; 2020 Dec; 288(6):661-681. PubMed ID: 33128834
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.